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This study was conducted to evaluate the effect of a reduced-dose 7-valent pneumococcal conjugate vaccine
(PCV) primary series followed by a 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster on
nasopharyngeal (NP) pneumococcal carriage. For this purpose, Fijian infants aged 6 weeks were randomized
to receive 0, 1, 2, or 3 PCV doses. Within each group, half received 23vPPS at 12 months. NP swabs were taken
at 6, 9, 12, and 17 months and were cultured for Streptococcus pneumoniae. Isolates were serotyped by multiplex
PCR and a reverse line blot assay. There were no significant differences in PCV vaccine type (VT) carriage
between the 3- and 2-dose groups at 12 months. NP VT carriage was significantly higher (P, <0.01) in the
unvaccinated group than in the 3-dose group at the age of 9 months. There appeared to be a PCV dose effect
in the cumulative proportion of infants carrying the VT, with less VT carriage occurring with more doses of
PCV. Non-PCV serotype (NVT) carriage rates were similar for all PCV groups. When groups were pooled by
receipt or nonreceipt of 23vPPS at 12 months, there were no differences in pneumococcal, VT, or NVT carriage
rates between the 2 groups at the age of 17 months. In conclusion, there appeared to be a PCV dose effect on
VT carriage, with less VT carriage occurring with more doses of PCV. By the age of 17 months, NVT carriage
rates were similar for all groups. 23vPPS had no impact on carriage, despite the substantial boosts in antibody
levels.
A recent review estimated that in the year 2000, more than
14 million episodes of serious pneumococcal disease occurred
worldwide, with more than 800,000 deaths of children under
the age of 5 years (30). Since the introduction of the 7-valent
pneumococcal conjugate vaccine (PCV) in the United States,
there has been a dramatic reduction in vaccine type (VT)
invasive pneumococcal disease (IPD) and a modest increase in
non-vaccine type (NVT) IPD (43), particularly due to serotype
19A (32, 39). Since nasopharyngeal (NP) carriage is an ante-
cedent event in IPD, the reduction or prevention of NP car-
riage may reduce the transmission of pneumococci. This has
occurred in the United States, where the widespread use of the
infant PCV has resulted in significant protection of unimmu-
nized individuals (12, 32), presumably mediated by reduced NP
carriage interrupting the transmission of pneumococci (12, 25).
Clinical trials using 5-, 7-, or 9-valent pneumococcal conju-
gate vaccines have shown a reduction in VT carriage compared
with that for unvaccinated infants (21, 23, 27) or toddlers (5, 6,
42). However, the overall rate of NP pneumococcal carriage
remained essentially unchanged, due to serotype replacement
with NVT pneumococci (5, 10, 23, 24, 27). Since the routine
introduction of PCV into infant national immunization sched-
ules, a number of carriage surveys have documented the effect
of PCV on NP pneumococcal carriage. Like the clinical trials,
all these studies have found that there has been a reduction in
VT carriage (4, 8, 11, 15, 17, 18, 26, 34). NVT colonization has
increased following vaccination, with serogroups 11 and 15
being commonly reported (4, 8, 11, 15, 18, 34), and more
recently, the newly identified serotype 6C has been reported
(31).
In the United Kingdom and some Scandinavian countries, a
2-PCV-dose schedule in infancy, followed by a PCV booster
toward the end of the first year of life, is routinely given. Little
is known about the effects of reduced-dose PCV schedules on
carriage and the consequent effects on herd immunity. Only
one other randomized controlled trial that evaluated the ef-
fects of reduced-dose pneumococcal conjugate vaccine sched-
ules on NP carriage has been published (40). Since serotype
replacement of NVT has occurred in both NP carriage and
IPD with the routine use of the infant PCV, it is important to
improve our understanding of this fine balance in order to
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determine the number of PCV doses that is likely to provide
protection from serious pneumococcal disease but may have a
lesser impact on carriage, in an attempt to minimize serotype
replacement.
In Fiji a vaccine trial with the aim of finding an optimal
pneumococcal vaccination strategy for resource-poor countries
has been completed. A phase II study was undertaken docu-
menting the safety, immunogenicity, and impact on carriage of
various schedules combining 1, 2, or 3 doses of PCV in infancy,
followed by a booster consisting of the 23-valent pneumococcal
polysaccharide vaccine (23vPPS). In this report, the effects of
the different vaccination schedules on overall NP pneumococ-
cal carriage rates are presented, along with rates of VT and
NVT carriage at the ages of 6, 9, 12, and 17 months.
MATERIALS AND METHODS
Study design. Details of the study design and randomization procedures have
been reported elsewhere (16, 37). In brief, following informed consent, healthy
infants in Suva, Fiji, were stratified by ethnicity and, within each stratum, were
randomized to receive either no vaccine or 1, 2, or 3 doses of PCV (Prevenar,
containing serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F at 2 g/serotype except for
serotype 6B [4 g]; Wyeth Vaccines) at the age(s) of 6 weeks, 6 and 14 weeks, or
6, 10, and 14 weeks. The vaccines coadministered at the ages of 6, 10, and 14
weeks were Tritanrix-HepB, Hiberix, and oral polio vaccine. At the age of 12
months, half the infants were randomized to receive 23vPPS (Pneumovax, 25
g/serotype; Merck & Co., Inc.), and all infants received a microdose (5 g/
serotype) of 23vPPS (mPPS) at the age of 17 months. All children received a
measles-rubella vaccine at the age of 12 months. The children randomized to
receive no PCV or 1 PCV dose in infancy had a single dose of PCV administered
at the age of 2 years. Table 1 shows the vaccination and blood collection sched-
ules for the eight groups.
The study was approved by the Fiji National Research Ethics Review Com-
mittee and the University of Melbourne’s Human Research Ethics Committee.
Parents or legal guardians signed a written document giving informed consent for
their children to participate in the study. The study was conducted and moni-
tored according to good clinical practice.
Nasopharyngeal swabs. Buffered cotton NP swabs (aluminum shaft-buffered;
Sarstedt, Australia) were taken at the ages of 6, 9, 12, and 17 months by
horizontal insertion into the nares by trained personnel. The swab was left in situ
for 5 s and was rotated, after which it was immediately placed in a sterile cryovial
tube (Simport, Canada) containing 1 ml of skim milk-tryptone-glucose-glycerol
(STGG) transport medium (28). This was transported in a chilled carrier to the
Colonial War Memorial Hospital Laboratory, Suva, Fiji, on the same day. The
swabs were processed according to the consensus guidelines of a World Health
Organization working group (29). The swabs were vortexed and either were
stored at 70°C until plating or were plated upon receipt in the laboratory. Fifty
microliters was inoculated onto a 2.5-mg/liter gentamicin–5% citrated sheep
blood (36) Columbia agar (Oxoid) plate. Plates were incubated at 37°C under 5%
CO2 for 18 to 24 h. Pneumococcal isolates were initially identified by alpha-
hemolysis, colony morphology, and optochin (Difco) sensitivity. Isolates with
intermediate optochin sensitivity were confirmed as pneumococci by bile solu-
bility testing. Single colonies were subcultured, and pure colonies were sent to
the Pneumococcal Reference Laboratory, Centre for Infectious Diseases and
Microbiology, ICPMR, Westmead, NSW, Australia, where they were serotyped
by multiplex PCR and a reverse line blot assay (20, 45). Ten percent were also
serotyped by a Quellung reaction using specific antisera (Statens Serum Institute,
Copenhagen, Denmark). Any discrepancy in serotype between the 2 methods
was resolved by a Quellung reaction. Laboratory staff members were blinded to
the group allocation for each isolate.
Questionnaires. At each of the 4 NP swab study visits, the following informa-
tion was collected by the study nurse in a parent/guardian interview: the number
of children in the household who were 5 years old, family income, exposure to
household cigarette smoking, breastfeeding status, whether the child had symp-
toms of an upper respiratory tract infection (coryza or cough) at the time of the
visit, and whether the child had received antimicrobials in the preceding 2 weeks.
The nurse did not ask about attendance at child care, since this is uncommon in
Fiji.
Statistical analysis. All case reporting forms were monitored prior to data
entry. Double data entry was performed on all case report forms. Cleaned data
were exported to Stata, version 9.0 (Stata Corporation, College Station, TX) for
analysis. Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F were classified as VT; all
other viable isolates, including those that were nontypeable, were classified as
NVT. Rates of NP carriage were calculated using the number of total pneumo-
coccal, VT, or NVT isolates in each group at each time point divided by the total
number of children who had an NP swab taken in each group at each time point.
Analyses comparing the proportions of infants with NP carriage of any pneu-
mococcus, VT pneumococci, and NVT pneumococci were performed using Fish-
er’s exact test. For each group, the cumulative proportion of children carrying
VT pneumococci was calculated. Due to the multiple comparisons, a P value of
0.01 was considered statistically significant.
RESULTS
A total of 552 children were enrolled in the study. The
characteristics of the study children are shown in Table 2. Age
at enrollment was comparable across the groups, but there
were minor differences in some of the characteristics, such as
higher exposure to cigarette smoking in the 2-PCV-dose group.
Of the 2,208 NP swabs planned, 90.8% were taken; of these,
47.8% were positive for Streptococcus pneumoniae. There were
959 pneumococcal isolates, of which 33 (3.4%) were nontype-
able and 13 (1.4%) were no longer viable for serotyping.
Table 3 shows the impacts of the different vaccination sched-
ules on overall NP carriage in the first 12 months of life. There
were no significant differences in NP pneumococcal carriage
between any of the groups at any time point. There was a trend
toward higher NP pneumococcal carriage rates in the single-
PCV-dose group than in the unvaccinated group at the age of
TABLE 1. Timing of vaccination, nasopharyngeal swabs, and blood draws for each of the 8 groups
Time point
Procedurea for group:
A B C D E F G H
6 wk PCV PCV PCV PCV
10 wk PCV PCV
14 wk PCV PCV PCV PCV PCV PCV
18 wk B B B B B B B
6 mo NP NP NP NP NP NP NP NP
9 mo NP, B NP NP, B NP NP, B NP NP NP
12 mo NP, B NP, B, 23vPPS NP, B NP, B, 23vPPS NP, B NP, B, 23vPPS NP, B, 23vPPS NP
12 1/2 mo B B B B
17 mo NP, B, mPPS NP, B, mPPS NP, B, mPPS NP, B, mPPS NP, B, mPPS NP, B, mPPS NP, B, mPPS NP, B, mPPS
18 mo B B B B B B B B
a PCV, 7-valent pneumococcal conjugate vaccine; B, blood test; 23vPPS, 23-valent pneumococcal polysaccharide vaccine; mPPS, microdose (20%) of 23vPPS; NP,
nasopharyngeal swabs.
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6 months (55% versus 42%; P, 0.04). For NP VT carriage, the
rates were significantly higher in the unvaccinated group at 9
months (16% versus 3%; P, 0.01) than in the 3-dose group.
There was a trend toward higher NP VT carriage rates (10%
versus 3%; P, 0.03) for the 2-PCV-dose group compared with
the 3-PCV-dose group and for the unvaccinated group com-
pared with the single-dose group (16% versus 7%; P, 0.03) at
the age of 9 months, as well as for the unvaccinated group
compared with the 3-dose group at 12 months (16% versus 7%;
P, 0.03). Figure 1 shows little difference in the cumulative
proportions of infants carrying VT pneumococci at the age of
6 months. However, there were substantial differences between
the PCV groups and the unvaccinated group in the cumulative
proportions of children carrying VT pneumococci at the ages
of 9 and 12 months. Moreover, there appeared to be a PCV
dose effect on the cumulative proportions of infants carrying
VT pneumococci at the ages of 9 and 12 months, with the
3-PCV-dose group having the lowest cumulative proportion
compared with the 2-dose and single-dose groups.
For NP NVT carriage, there were no significant differences
between any groups at any time point. Still, there was a trend
toward higher NP NVT carriage in the 3-dose group compared
with the unvaccinated group at the ages of 6 (40% versus 24%;
P, 0.03) and 9 (43% versus 27%; P, 0.01) months and in the
single-dose group compared with the unvaccinated group at
the ages of 6 (43% versus 24%; P, 0.01), 9 (42% versus 27%;
P, 0.03), and 12 (43% versus 29%; P, 0.01) months.
At the age of 17 months, there were no significant differ-
ences in total pneumococcal and VT carriage rates between
those groups that had or had not received 23vPPS or by num-
ber of PCV doses (Fig. 2). There was a trend toward higher VT
carriage among those that had received no PCV or 1 PCV dose
than in the 2- or 3-PCV-dose groups (Fig. 2). Figure 1 shows
the cumulative proportion of VT carriage at 17 months by PCV
and 23vPPS group allocation. Minimal differences can be seen
in VT carriage within each PCV group, whether individuals
had or had not received 23vPPS at the age of 12 months.
However, those who had received 23vPPS alone had the high-
est cumulative proportion of VT carriage at the age of 17
months (P, 0.001) compared to the group receiving 3 PCV
doses only. There were no significant differences in NVT car-
riage rates between those groups that had or had not received
23vPPS at the age of 12 months (Table 4). Upon further anal-
ysis by PCV group allocation, there were no significant differ-
ences in NVT carriage at the age of 17 months between any
PCV groups.
Serotypes 19F and 23F were the most frequently carried
PCV serotypes in all groups in the first 12 months, and 6B was
TABLE 2. Characteristics of infants by group allocation at enrollment and at each of the 4 nasopharyngeal swab visits
Time point and parameter
Valuea for individuals receiving the following no. of PCV doses, with or without 23vPPS at 12 mo:
3 PCV doses 2 PCV doses 1 PCV dose No PCV
No 23vPPS 23vPPS No 23vPPS 23vPPS No 23vPPS 23vPPS 23vPPS No 23vPPS
At enrollment
No. of children 71 65 76 80 62 66 63 69
Male 38 (54) 33 (51) 31 (41) 39 (49) 31 (50) 28 (42) 32 (51) 32 (46)
Median age (wks) 6.7 6.5 6.5 6.4 6.5 6.5 6.5 6.4
Ethnicity
Indigenous Fijian 39 (55) 43 (66) 48 (63) 58 (73) 41 (66) 42 (64) 35 (55) 45 (65)
Indo-Fijian 29 (41) 17 (26) 24 (32) 21 (26) 17 (27) 22 (33) 20 (32) 20 (29)
Other 3 (4) 5 (8) 4 (5) 1 (1) 4 (7) 2 (3) 8 (13) 4 (6)
Median wt (g) 4,850 5,000 4,775 4,800 4,900 4,750 4,750 4,800
Median no. of children 5 yr
old in household (range)
1.5 (1–4) 2 (1–5) 1 (1–3) 1 (0–4) 2 (0–4) 2 (1–4) 2 (1–5) 2 (1–4)
Median weekly incomeb (range) 74 (15–270) 74 (24–490) 74 (20–392) 72 (10–613) 64 (10–245) 62 (20–343) 54 (20–294) 61 (0–294)
Exposure to cigarette smoking 32 (49) 22 (36) 39 (54) 41 (54) 26 (44) 31 (49) 30 (50) 36 (54)
At the age of 6 mo
No. of children 66 61 72 76 59 63 60 67
Breastfeeding 55 (83) 50 (82) 57 (79) 66 (87) 50 (85) 50 (79) 55 (92) 56 (84)
Current URTIc 18 (27) 15 (25) 20 (28) 30 (39) 16 (27) 14 (22) 20 (33) 20 (30)
Antimicrobials in prior 2 wks 9 (14) 5 (8) 11 (15) 10 (13) 6 (10) 7 (11) 5 (8) 13 (19)
At the age of 9 mo
No. of children 62 60 71 75 55 63 60 66
Breastfeeding 44 (71) 39 (65) 46 (65) 57 (76) 42 (76) 45 (71) 46 (77) 51 (77)
Current URTI 18 (29) 18 (30) 23 (32) 27 (36) 20 (36) 20 (32) 19 (32) 26 (39)
Antimicrobials in prior 2 wks 3 (5) 5 (8) 7 (10) 8 (11) 5 (9) 3 (5) 3 (5) 3 (5)
At the age of 12 mo
No. of children 61 53 71 72 54 61 59 66
Breastfeeding 32 (52) 26 (49) 37 (52) 45 (63) 19 (35) 38 (62) 45 (76) 44 (67)
Current URTI 13 (21) 15 (28) 15 (21) 13 (18) 14 (26) 10 (16) 10 (17) 19 (29)
Antimicrobials in prior 2 wks 4 (7) 9 (17) 6 (8) 9 (13) 8 (15) 5 (8) 5 (8) 6 (9)
At the age of 17 mo
No. of children 60 49 68 67 49 59 57 63
Breastfeeding 23 (38) 16 (33) 27 (40) 29 (43) 19 (39) 26 (44) 29 (51) 27 (43)
Current URTI 13 (22) 19 (39) 22 (32) 14 (21) 16 (33) 13 (22) 18 (32) 18 (29)
Antimicrobials in prior 2 wks 1 (2) 7 (14) 7 (10) 4 (6) 2 (4) 3 (5) 6 (11) 10 (16)
a Values are numbers (percentages) unless otherwise indicated.
b In U.S. dollars, with an exchange rate of 0.49 U.S. dollar for 1 Fijian dollar.
c URTI, upper respiratory tract infection.
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the most frequently carried serotype by the age of 17 months.
Of the non-PCV serotypes, 6A and 19A were the most fre-
quently carried serotypes throughout the study.
DISCUSSION
Our findings suggested a PCV dose effect on VT carriage,
with 3 PCV doses appearing to have a greater effect on VT
carriage than fewer PCV doses. Unfortunately, the sample size
was too small to evaluate the impact of the different vaccina-
tion groups on the carriage of individual serotypes. We found
that a single PCV dose results in some initial reduction in VT
carriage (though not statistically significant), which, along with
FIG. 1. Cumulative proportions of infants carrying a 7-valent pneu-
mococcal conjugate vaccine (PCV) type at the ages of 6, 9, 12, and 17
months (m) by PCV and 23-valent pneumococcal polysaccharide vac-
cine (23vPPS) group allocation.
FIG. 2. Nasopharyngeal (NP) carriage rates of all pneumococcal
serotypes and 7-valent pneumococcal conjugate vaccine (PCV) sero-
types (VT) at the age of 17 months following either no vaccination or
1, 2, or 3 doses of PCV in infancy with or without a booster consisting
of a 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12
months (12m). For all comparisons within the same PCV dosage group
between those receiving or not receiving 23vPPS at 12 months, P values
were not significant (all 0.45).
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immunogenicity data (35), provides supportive evidence that
one dose may offer some early protection from IPD. Early
differences (though not statistically significant) in NVT car-
riage rates between groups were no longer evident by the age
of 17 months. Furthermore, the addition of 23vPPS at the age
of 12 months had no impact on carriage, despite the substantial
boosts in antibody levels observed (38).
One of the key questions is the duration of the effect of
reduced-dose schedules on NP carriage. In this study we found
that the reduction in VT carriage rates was sustained to the age
of 17 months following a 3- or 2-PCV-dose schedule. There is
only one other randomized and published study reporting the
effect of reduced-dose PCV schedules on NP carriage. This
study, from the Netherlands, compared carriage rates follow-
ing 2 PCV doses at the ages of 2 and 4 months versus a 2-plus-1
schedule at the ages of 2, 4, and 11 months or no vaccination
(control group). Both vaccinated groups had significantly lower
rates of VT carriage in the second year of life than controls
(40). The booster dose resulted in lower rates of VT carriage
at 18 months than those seen with no booster dose (24% versus
16%). However, by the age of 2 years, the two vaccinated
groups had similar VT carriage rates (15% each) (40). Simi-
larly, in a case-control study, Gambian infants vaccinated with
either 3 or 2 doses of a 5-valent pneumococcal conjugate vac-
cine in infancy, followed by 23vPPS at the age of 18 months,
showed significantly lower VT carriage rates than unvaccinated
matched controls at the age of 2 years (27).
There are a number of studies evaluating the duration of the
effect of a 3-PCV-dose schedule on VT carriage. In one study,
the effects on VT colonization were no longer evident by the
ages of 2 to 5 years following 3 PCV doses in infancy and the
23vPPS at the age of 13 months (21). Similarly, a study in
South Africa found no differences among non-HIV-infected
children in VT colonization in the 3-PCV-dose group com-
pared with the placebo group 5 years after vaccination in in-
fancy (22a). In contrast, in the Gambia, the effects on carriage
persisted at least 16 months postvaccination when 3 doses of an
infant 9-valent pneumococcal conjugate vaccine were admin-
istered (2). In another study, following the vaccination of tod-
dlers under the age of 2 years, the reduction in VT carriage
continued for at least 1 year (6); in 2 other studies, it continued
to the age of 4 years but not beyond (5, 42). Since the routine
introduction of PCV into national infant immunization sched-
ules, a number of carriage surveys have documented the effect
of PCV on NP pneumococcal carriage. Like the clinical trials,
all these studies have reported a reduction in VT carriage (4,
8, 11, 15, 17, 18, 26, 34), particularly in those children who are
up to date with their immunizations (4, 17, 26), have had a
PCV booster in the second year of life (4, 11), or have not had
prolonged intervals between PCV doses (17).
One of the disadvantages of the currently available PCV is
serotype replacement by NVT pneumococci filling the vacant
ecological niche following vaccination (22). In our study,
higher (though not statistically significant) NVT carriage rates
were found in the PCV groups than in unvaccinated controls in
the first 12 months of life. However, by the age of 17 months,
this trend was no longer evident, suggesting that this initial
effect was not sustained. Our NVT carriage rate (approxi-
mately 40%) is higher than those reported by the reduced-dose
Netherlands study: 15 to 17% for the vaccinated groups and
8% for the unvaccinated control group (40). The NVT carriage
rates reported in observational studies of children from indus-
trialized countries following PCV tend to be lower (18% in the
United States [11] and 15.5% in France [4]). However, NVT
carriage rates following vaccination of children from nonindus-
trialized countries (77% in the Gambia [27] and 36% in South
Africa [23]) and high-risk disadvantaged communities (39.2%
for Navajo and White Mountain Apache children [24]) tend to
be higher. This suggests that the impact of PCV on NVT
carriage may be greater in geographical settings with high
burdens of pneumococcal disease, since the direct and indirect
effects of PCV differ with age and the presence of underlying
conditions such as HIV (9). Ongoing surveillance is needed to
detect changes in rates of NVT IPD, in addition to VT IPD,
following the introduction of PCV.
To our knowledge, this is the first published randomized
study to show the impact of a single PCV dose on NP carriage.
There appeared to be a PCV dose effect on VT carriage, with
a single PCV dose having less effect on VT carriage than a 2-
or 3-dose schedule. A single PCV dose initially reduced VT
carriage (though not statistically significantly), but this effect
was not sustained, and by the age of 12 months, there was no
difference in rates between the single-dose group and the un-
vaccinated controls. The single-dose group had a higher
(though not statistically significantly) NVT carriage rate than
unvaccinated controls up to the age of 12 months, but there
were no significant differences in NVT carriage rates between
any of the groups by the age of 17 months. In contrast, the
results from a series of prevalence surveys in Canada showed
that children who had received no vaccination or 1 or 2 PCV
doses were less likely to be colonized with NVT pneumococci
than those who had received 3 PCV doses (18). In a small
observational study coinciding with a shortfall of PCV supply
in the United States, NVT carriage rates were similar for those
children who had received 1 or 2 doses (22 versus 27%) but
higher for the 3-dose group (47%) (17). The data from our
study, combined with our previously reported immunogenicity
data, in which a single PCV dose elicited significant responses
for all serotypes post-primary series compared with the unvac-
cinated group (35), provide additional evidence that a single
PCV dose in infancy would offer some protection in the first 12
months of life. Moreover, memory responses were most pro-
found for children who had received only a single dose of PCV
previously, compared with the 2- or 3-dose groups (38). The
results from this study and previously published immunogenic-
ity data (35, 38) raise the intriguing possibility that a schedule
TABLE 4. Nasopharyngeal (NP) carriage of all pneumococci and
non-PCV serotypes at the age of 17 months in those who did or
did not receive the 23-valent pneumococcal polysaccharide
vaccine (23vPPS) at the age of 12 months
Pneumococcus
No. (%) of children with
NP pneumococcal carriage:
P OR (95% CI)aBoosted with
23vPPS
(n  232)
Not boosted
with 23vPPS
(n  240)
All pneumococci 109 (47) 111 (46) 1.000 0.99 (0.71–1.4)
NVT 89 (38) 93 (39) 0.733 0.87 (0.44–1.72)
a OR, unadjusted odds ratio; 95% CI, 95% confidence interval.
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based on a single dose of vaccine early in infancy with an early
booster might provide adequate protection while avoiding the
problems of serotype replacement.
The 12-month 23vPPS booster had no additional effect on
pneumococcal carriage rates and no statistically significant ef-
fect on VT or NVT carriage rates despite significant boosts in
antibody levels (38). Similarly, studies using other pneumococ-
cal polysaccharide vaccines have shown no effect on pneumo-
coccal carriage (3, 7, 14, 34, 44). PCV followed by 23vPPS
given to 1- to 7-year-old children with recurrent acute otitis
media in the Netherlands showed no beneficial effect from the
booster vaccine (41). In addition to having no effect on car-
riage, 23vPPS may have deleterious immunological effects. In
this study, there was a suggestion that the VT carriage rate was
higher at the age of 17 months in the group that received
23vPPS alone than in all other groups. Despite our study pre-
viously demonstrating the potential value of a PCV/23vPPS
schedule (38), immunological hyporesponsiveness to a small
rechallenge dose of 23vPPS has been demonstrated (37).
These findings suggested that additional immunization with
23vPPS following a primary series of PCV does not provide an
added benefit for antibody production and instead results in
impaired immune responses following a subsequent pneumo-
coccal polysaccharide antigen challenge.
Although 2 or 3 doses have an impact on VT carriage, the
overall pneumococcal carriage rates did not change, due to the
increase in NVT carriage. This has been consistently found in
many other studies in different settings (5, 8, 10, 11, 15, 18, 23,
24, 26, 33, 42). Considering this effect and the potential loss of
natural boosting after widespread implementation of reduced
doses, ongoing surveillance of the impact on carriage and IPD
is important, since a booster dose may be necessary for long-
term protection (13, 19).
In conclusion, although the sample size was small, there
appeared to be a PCV dose effect on VT carriage, with less VT
carriage occurring with more doses of PCV. A single PCV dose
resulted in some initial reduction in VT carriage rates, and
along with supportive immunogenicity data, this finding pro-
vides further evidence that a single dose would offer some
protection from IPD. There was no significant difference in
NVT carriage among the groups. The addition of 23vPPS at
the age of 12 months had no impact on carriage.
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